Summary.-Adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) levels of peripheral blood mononuclear cells were measured in 34 patients with various types of solid tumours. The mean ADA activity was found to be significantly lower than in controls (P < 0.005). Patients with nonresectable tumour or with recurrence after radical surgery showed low ADA levels, while patients operated upon and without recurrence had enzymatic activity not different from that of normal controls. The mean value of PNP activity was similar to that of normal controls; no differences were observed between operated patients without recurrence and cases with nonresectable tumour or with recurrence after surgical treatment. No effects on ADA and PNP levels appeared to be induced by chemotherapy.
Summary.-Adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) levels of peripheral blood mononuclear cells were measured in 34 patients with various types of solid tumours. The mean ADA activity was found to be significantly lower than in controls (P < 0.005). Patients with nonresectable tumour or with recurrence after radical surgery showed low ADA levels, while patients operated upon and without recurrence had enzymatic activity not different from that of normal controls. The mean value of PNP activity was similar to that of normal controls; no differences were observed between operated patients without recurrence and cases with nonresectable tumour or with recurrence after surgical treatment. No effects on ADA and PNP levels appeared to be induced by chemotherapy. ADENOSINE D)EAMINASE (EC 3.5.4.4 ., ADA) and purine nucleoside phosphorylase (EC 2.4.2.1., PNP) are two enzymes involved in the purine salvage pathway. ADA and PNP activities are present in normal lymphocytes and appear to be necessary for an effective immune response. The first report of impaired immunological function associated with ADA deficiency was by Giblett et al. (1972) in a patient with severe combined immunodeficiency. This finding, which has been substantiated by other groups (Meuwissen et al., 1975; Parkman et al., 1975) , has stimulated great interest, because it was the first description of an enzymatic defect linked to a disorder of specific immunity. Subsequently, PNP was shown to be deficient in some patients with severe T-cell deficiency and apparently normal humoral immunity (Giblett et al., 1975; Stoop et al., 1977; Gelfand et al., 1978; Sandman et al., 1977; Chen et al., 1979) . The biochemical events which result in immune malfunction are unclear, but inherited disorders of purine degradation may impair the immune response.
Lymphocyte ADA activity has been investigated in acquired diseases also and a possible relationship between its levels and immunological changes has been suggested. Increased ADA activity was found in typhoid fever and brucellosis (Galanti et al., 1981) , in patients rejecting transplanted kidneys (Lum et al., 1978) , in acute leukaemia (Smyth & Harrap, 1975) and in some patients with lymphoma (Meier et al., 1976) . In contrast, low ADA levels were reported in chronic lymphocytic leukaemia (Tung et al., 1976) and in liver cirrhosis (Galanti et al., 1978 Boyum (1968) . Heparinized peripheral blood was diluted 1:1 with Hanks' solution (pH 7.5) and layered on to a Ficollpaque gradient. After centrifugation at 400 g for 30 min, the lymphocyte halo was removed by aspiration and washed twice in Hanks' solution. The lymphocyte suspensions, containing 2-5 x 106 cells per ml, with contamination by erythrocytes and granulocytes of less than 500, were sonicated for 45 sec at 25 kc/ sec (cell disruption was ascertained microscopically). The lymphocyte extracts were centrifuged at 800 g for 10 min and the supernatants were immediately used for analysis.
ADA and PNP determination.-ADA activity was measured by a colorimetric mehod (Giusti, 1974) based on the determination of the amount of NH3 released in the reaction mixture, wrhich contained 1 ml of 20mM adenosine in 50mM phosphate buffer at pH 7-2 and 100 ,ul of lymphocyte extract. Control tubes were prepared by omitting the substrate or the enzyme source. After 60min incubation at 37°C, NH3 was assayed by Chaney and Marbach's reagents (Chaney & Marbach, 1962) and the optical density was measured at 628 nm. The enzyme activity was calculated bv referring to a standard curve of ammonium sulphate in buffer. PNP activity was measured in a final volume of 1 035 ml containing 1 ml of 5mM inosine in 50mM phosphate buffer at pH 7 5, 25 ,ul of lymphocyte extract and 10 ,ul of xanthine oxidase (10 mg/ml, 04 u/mg, Boehringer-Mannhein). The ADA value is lower than the control mean (P < 0.001). In contrast, the 16 tumour * patients previously operated and without recurrence showed a mean ADA value no different from that of controls. * Data concerning lymphocyte PNP activity and reported in Table I show that the mean value for tumour patients does not differ from that of the controls; no sig-* nificant differences were found even when our patients were considered in relation * to previous surgery or to recurrence after surgery.
To evaluate a possible action of chemo-* therapy on lymphocyte enzyme levels, we * have allocated tumour patients according to cytostatic treatment (Table II) 
DISCUSSION
The relationship between abnormalities of purine catabolism and immune function found in inherited immune-deficiency diseases has stimulated investigations on levels of ADA and PNP activities in peripheral lymphocytes from patients with acquired diseases. Data concerning cancer patients are still scanty, but a low mean value of ADA activity is proven in patients with solid tumours (Uberti et al., 1976; Ogawa et al., 1978) .
In the present study we have measured ADA and PNP levels in peripheral lymphocytes from 34 patients with various solid tumours. For ADA activity, our results confirm a significant reduction in tumour patients. Our data also suggest that ADA levels are related to cancer progression, i.e., low levels are found in patients with advanced tumour; in our series, in fact, 89% of patients with advanced tumour showed individual ADA values below the control range. The 16 cases without recurrence after surgical removal of the primary tumour had a mean ADA value similar to that of controls, while 3/4 patients with recurrence after surgery showed single ADA values lower than the control range.
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Whether decreased lymphocyte ADA levels are related to the presence of neoplastic tissue, and whether normal ADA levels could be restored by radical tumour removal, need to be studied. We have no preoperative data on lymphocyte ADA levels from our patients undergoing surgery and in the literature there are no data on when an ADA decrease might occur after surgical removal of a tumour.
Finally, lymphocyte ADA activity appears to be unaffected by chemotherapy. In our series the patients surgically treated, without recurrence, and on chemotherapy, showed control levels of ADA and patients with advanced cancer, whether on chemotherapy or not, showed low ADA levels.
As far as lymphocyte PNP activity is concerned, our control values range from 72-02 to 125-10 nmol/min/mg protein and are similar to those found by others (Ogawa et a ., 1978; Sidi et al., 1979; Mejer & Nygaard, 1979) . Lymphocyte PNP levels of tumour patients do not differ from the controls, even when they are considered in relation to previous surgery, to degree of neoplastic growth and to chemotherapy.
